Monopar Therapeutics (MNPR) Net Cash Flow Growth (1y) (2018 - 2025)
Monopar Therapeutics (MNPR) Net Cash Flow Growth (1y) (2018 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 301.06% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Monopar Therapeutics | 707.36 Mn | 645.53 Mn | - | -265.69% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -265.69% |
| Sep 30, 2025 | 84,636.59% |
| Jun 30, 2025 | 87.75% |
| Mar 31, 2025 | -1,223.96% |
| Dec 31, 2024 | 2,162.54% |
| Sep 30, 2024 | 93.89% |
| Jun 30, 2024 | -213.10% |
| Mar 31, 2024 | 122.17% |
| Dec 31, 2023 | 128.92% |
| Sep 30, 2023 | 21.46% |
| Jun 30, 2023 | 208.52% |
| Mar 31, 2023 | 1.39% |
| Dec 31, 2022 | -198.16% |
| Sep 30, 2022 | -11.32% |
| Jun 30, 2022 | 3.77% |
| Mar 31, 2022 | -127.65% |
| Dec 31, 2021 | -63.46% |
| Sep 30, 2021 | -135.91% |
| Jun 30, 2021 | -2,814.45% |
| Mar 31, 2021 | 1,554.71% |